News
CHMP recommends a change to the indication of Xromi (hydroxycarbamide) to include prevention of sickle cell disease complications.- Nova Laboratories.
On 22 February 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Xromi.
The marketing authorisation holder for this medicinal product is Nova Laboratories Ireland Limited. The CHMP adopted an extension to the existing indication to include prevention of sickle cell disease complications in infants from 9 months of age.
Condition: Sickle Cell Disease
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.